compounds but further have r 3 and r 4 selected from hydrogen or hydroxy particularly in the position ortho to the substituent having the z group additionally the compounds having the limitations of the more preferred compounds and additionally having z defined as the coor 5 or str75 are the most preferred compounds the activity of the compounds of the formula i is shown in vitro in an nmda receptor binding assay based on the use of 3 h cpp as antagonist ligand in a manner essentially as set out by b e murphy et al in j pharm exp ther 240 778 1987 examples i 1 i 2 and i 3 all exhibit cpp binding activity of ic 50 better than 100 u03bcm the compounds of the present invention can be shown to be antagonists as inhibitors of 3 h tcp tissue binding in an in vitro assay described in eur j pharmacol 123 467 1986 and neurosci lett 76 221 1987 or as inhibitors of glutamate stimulated acetylcholine release from striatal slice preparations as disclosed in j pharm exp ther 240 737 1987 in vivo activity for the compounds of the present invention is shown by selected compounds in the assays of ep publication number 318935 incorporated herein by reference which are generally accepted to establish the utility for the treatment of diseases as noted above therefore the compounds of formula i and their pharmacologically acceptable acid addition salts are effective agents in the prophylaxis and or therapeutic treatment of disorders responsive.